Comparative Pharmacology
Head-to-head clinical analysis: ALDARA versus IMIQUIMOD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDARA versus IMIQUIMOD.
ALDARA vs IMIQUIMOD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates immune cells, leading to the production of cytokines such as interferon-alpha, which promotes antiviral and antitumor activity.
Imiquimod is an immune response modifier that acts as a toll-like receptor 7 (TLR7) agonist, activating TLR7 on dendritic cells and macrophages, leading to the production of cytokines such as interferon-alpha, tumor necrosis factor-alpha, and interleukins (IL-1, IL-6, IL-8, IL-12). This enhances innate and adaptive immune responses, promoting antiviral and antitumor activity.
Apply a thin layer to the target lesion(s) 3 times per week (e.g., Monday, Wednesday, Friday) for up to 16 weeks. Do not occlude. Wash hands before and after application.
Apply 5% cream to affected area 3 times weekly (e.g., Monday, Wednesday, Friday) for up to 16 weeks; leave on skin for 8 hours.
None Documented
None Documented
Clinical Note
moderateImiquimod + Digoxin
"Imiquimod may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateImiquimod + Digitoxin
"Imiquimod may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateImiquimod + Deslanoside
"Imiquimod may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateImiquimod + Acetyldigitoxin
"Imiquimod may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 2-4 hours after topical application; no systemic accumulation with once-daily dosing
The terminal elimination half-life of systemically absorbed imiquimod after topical application is approximately 30 hours (range 24-36 hours) in patients with normal renal function, supporting once-daily dosing or application three times per week.
Renal: negligible; biliary/fecal: 94% as unchanged drug and metabolites
Following topical application, systemic absorption is minimal (<0.9% of applied dose). Systemically absorbed imiquimod is primarily excreted in urine (approximately 90% as unchanged drug and metabolites) and feces (approximately 10%).
Category C
Category C
Immune Response Modifier
Immune Response Modifier